Profound Medical Corp. (PROF)
| Market Cap | 250.05M +76.3% |
| Revenue (ttm) | 18.81M +58.6% |
| Net Income | -38.90M |
| EPS | -1.22 |
| Shares Out | 36.34M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 189,358 |
| Open | 7.29 |
| Previous Close | 7.16 |
| Day's Range | 6.81 - 7.89 |
| 52-Week Range | 3.76 - 8.95 |
| Beta | 0.50 |
| Analysts | Strong Buy |
| Price Target | 12.00 (+75.18%) |
| Earnings Date | May 7, 2026 |
About PROF
Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company’s lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-t... [Read more]
Financial Performance
In 2025, Profound Medical's revenue was $16.10 million, an increase of 50.73% compared to the previous year's $10.68 million. Losses were -$42.57 million, 53.0% more than in 2024.
Financial StatementsAnalyst Summary
According to one analyst, the rating for PROF stock is "Strong Buy" and the 12-month stock price target is $12.0.
News
Profound Medical price target lowered to $10 from $12 at Stifel
Stifel analyst Rick Wise lowered the firm’s price target on Profound Medical (PROF) to $10 from $12 and keeps a Buy rating on the shares.
Q1 2026 Profound Medical Corp Earnings Call Transcript
Q1 2026 Profound Medical Corp Earnings Call Transcript
Profound Medical Earnings Call Transcript: Q1 2026
Q1 2026 revenue more than doubled year-over-year, with improved margins and a reduced net loss. Strong clinical evidence and payer coverage are driving adoption, and full-year revenue is projected to grow 56% to CAD 25 million, with gross margin expected at 70% or higher.
Profound Medical Reports Strong First Quarter 2026 Financial Results
– Quarterly results marked by 104% revenue growth and improved operating performance – – Company issues full-year 2026 revenue guidance – – Announces Humana is now covering the TULSA Procedure™ – TORO...
Profound Medical Corp (PROF) Q1 2026 Earnings Report Preview: What to Expect
Profound Medical Corp (PROF) Q1 2026 Earnings Report Preview: What to Expect
Profound Medical Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference
TULSA, an AI-driven, MRI-guided, incision-free prostate therapy, is gaining traction with strong clinical data, expanding insurance coverage, and a growing addressable market in prostate cancer and BPH. High margins and partnerships with major MRI companies support robust financial growth.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF
NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Profound Medical Corp. (“Profound” or the “Company”) (NASDAQ: PROF). Such investors are ad...
Profound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference
TORONTO, April 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered,...
Profound Medical Corp. Investigated by the Portnoy Law Firm
LOS ANGELES, April 09, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Profound Medical Corp. , (“ Profound " or the "Company") ( NASDAQ : PROF) investors that the firm has initiated an investi...
Incision-Free, MRI-Guided Prostate Treatment with Profound's TULSA-PRO® to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting
TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered,...
Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone
TORONTO, March 27, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered,...
Top 3 Health Care Stocks That Are Set To Fly In March
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Profound Medical's (PROF) TULSA Procedure Shows Superior Safety Outcomes
Profound Medical's (PROF) TULSA Procedure Shows Superior Safety Outcomes
Profound Medical Transcript: Status update
Six-month CAPTAIN trial data show TULSA outperforms surgery in safety and functional recovery for intermediate-risk prostate cancer, with rapid patient recovery and strong quality-of-life outcomes. TULSA's inclusion in the 2025 NCCN guidelines and robust evidence base position it for broader adoption and payer coverage as further oncologic data matures.
Profound Medical reports CAPTAIN trial meets primary safety endpoint
Profound Medical (PROF) announced superiority on the prespecified, primary safety endpoint in the Level 1 post-market CAPTAIN randomized controlled trial comparing the TULSA Procedure with robotic rad...
CAPTAIN Trial Comparing Profound's MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence
– First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to successfully recruit to target enrollment –
Profound Medical (PROF) Awaits Key Clinical Data Presentation
Profound Medical (PROF) Awaits Key Clinical Data Presentation
Profound Medical pullback after Q4 report ‘misguided,’ says Lake Street
Lake Street analyst Ben Haynor views last Friday’s reaction to Profound Medical’s (PROF) Q4 results as “misguided” and resulting in “major news being overlooked,” namely that the first clinical CAPTAI...
Profound Medical Corp (PROF) Q4 2025 Earnings Call Highlights: Revenue Surge and Strategic ...
Profound Medical Corp (PROF) Q4 2025 Earnings Call Highlights: Revenue Surge and Strategic Expansions Amidst Challenges
Q4 2025 Profound Medical Corp Earnings Call Transcript
Q4 2025 Profound Medical Corp Earnings Call Transcript
Profound Medical (PROF) Reports Q4 Revenue Below Expectations
Profound Medical (PROF) Reports Q4 Revenue Below Expectations
Profound Medical Q4 Earnings Assessment
Profound Medical (NASDAQ: PROF) reported its Q4 earnings results on Thursday, March 5, 2026 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Profound Medical missed es...
Profound Medical Earnings Call Transcript: Q4 2025
Q4 2025 revenue rose 43% year-over-year to $6M, with gross margin at 67% and a net loss of CAD 8.2M. The company expects high double-digit to low triple-digit revenue growth in 2026, driven by TULSA-PRO adoption, new clinical evidence, and favorable reimbursement trends.
Profound Medical reports Q4 EPS (27c), consensus (28c)
Reports Q4 revenue $5.98M, consensus $10.53M. “We continued to execute well, delivering record revenues, an expanded TULSA-PRO installed base, and a stronger capital sales pipeline again in the fourth...
Profound Medical's Earnings: A Preview
Profound Medical (NASDAQ: PROF) is set to give its latest quarterly earnings report on Thursday, 2026-03-05. Here's what investors need to know before the announcement. Analysts estimate that Profoun...